Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.81
- Piotroski Score 1.00
- Grade Buy
- Symbol (OVID)
- Company Ovid Therapeutics Inc.
- Price $1.04
- Changes Percentage (-1.89%)
- Change -$0.02
- Day Low $1.02
- Day High $1.07
- Year High $4.10
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/15/2024
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $11.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.72
- Trailing P/E Ratio -4.11
- Forward P/E Ratio -4.11
- P/E Growth -4.11
- Net Income $-52,338,959
Income Statement
Quarterly
Annual
Latest News of OVID
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Vaccination rates for flu and Covid are low this season, CDC says
Vaccination rates for flu, Covid-19, and RSV in the U.S. are low among adults. CDC data shows 35% got flu shots and 18% received Covid vaccines....
By NBC News | 1 day ago -
Delaying routine care was least bad of 'awful options', Matt Hancock tells Covid inquiry
Former health secretary Matt Hancock admitted that canceling non-urgent treatments during the pandemic was the "least bad" option. He defended the decision to postpone routine care, despite being chal...
By The Guardian | 1 day ago -
Japanese-inspired San Francisco eatery finds footing in post-COVID real estate market
As remote work and city migration continue, urban areas are adapting to keep neighborhoods vibrant. Small businesses like Komeya No Bento in San Francisco are thriving by offering unique Japanese-insp...
By CBS News | 1 day ago
